Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL Oral Solution with $0 Co-Pay
Eton Pharmaceuticals has in-licensed U.S. commercialization rights to HEMANGEOL (propranolol hydrochloride) oral solution from Pierre Fabre, effective May 1. The FDA-approved orphan drug will be distributed via its Eton Cares program, offering a $0 co-pay initiative expected to be accretive to 2026 earnings.
1. Acquisition of HEMANGEOL Rights
Eton Pharmaceuticals has in-licensed exclusive U.S. commercialization rights to HEMANGEOL oral solution from Pierre Fabre, effective May 1. HEMANGEOL is the only FDA-approved systemic therapy for proliferating infantile hemangiomas.
2. Eton Cares Distribution Program
The company will integrate HEMANGEOL into its Eton Cares patient support program, which offers prescription fulfillment, insurance benefits investigation, educational support, and $0 co-pay assistance for qualifying patients.
3. Patient Population and Treatment Protocol
Approximately 5,000 to 10,000 infants in the United States initiate HEMANGEOL treatment annually, typically between five weeks and five months of age, with therapy lasting around six months.
4. Financial and Strategic Impact
The transaction is expected to be accretive to 2026 earnings and marks Eton's tenth commercial product, advancing its goal to build the largest rare disease portfolio in the U.S.